3 completed, 2 enrolling by invitation, 2 recruiting, 1 not yet recruiting. 6 Phase 4, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Completed 3, Enrolling by invitation 1, Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow Harrow Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks Vevye®, Cyclosporine emulsion - Dry Eye Disease (DED) | Phase 4 | Not yet recruiting | Baylor College of Medicine | 60 | 2026-09-01 | 2026-06-03 |
| Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction Vevye(Cyclosporine 0.1% Ophthalmic Solution) - Meibomian Gland Dysfunction (MGD) | Phase 4 | Recruiting | University of Alabama at Birmingham | 48 | 2026-06-01 | 2026-06-09 |
| A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery Sham (No Treatment), TRIESENCE (triamcinolone acetonide injectable suspension) - Postoperative Ocular Inflammation, Postoperative Ocular Pain | Phase 3 | Enrolling by invitation | Harrow Inc | 250 | 2026-05-25 | 2026-09-22 |
| Patient Comfort Following Intravitreal Injections Using Iheezo Versus Standard Anesthesia Iheezo, Lidocaine pledget - Macular Degeneration, Diabetic Retinopathy | Phase 4 | Completed | Retina Consultants of Delmarva | 50 | 2026-05-20 | 2026-08-21 |
| Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study Cyclosporine ophthalmic solution 0.1% - Dry Eye | Recruiting | Neuro-Ophthalmology of Texas | 50 | 2026-03-31 | 2026-05-05 | |
| Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Sham Subconjunctival Injection, Proparacaine Hydrochloride Ophthalmic Solution 0.5% - Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD) | Phase 4 | Enrolling by invitation | Harrow Inc | 236 | 2026-03-31 | 2026-04-07 |
| The Effects of Low Viscosity Chloroprocaine Ophthalmic Gel 3% on the Bactericidal Action of Povidone-Iodine Chloroprocaine ophthalmic gel 3% - Antiseptic, Anesthesia, Local | Phase 4 | Completed | Harrow Inc | 100 | 2023-07-15 | 2025-09-16 |
| Tolerability Comparison of Flarex to Lotemax SM Fluorometholone Acetate Ophthalmic Suspension 0.1%, Loteprednol Etabonate Ophthalmic Gel 0.38% - Ocular Inflammation, Keratoconjunctivitis | Phase 4 | Completed | Harrow Inc | 40 | 2021-05-01 | 2026-09-22 |
Dry Eye Syndromes (4) · Diabetic Retinopathy (2) · Macular Degeneration (2) · Retinal Vein Occlusion (2) · Keratoconjunctivitis (1) · Meibomian Gland Dysfunction (1) · Postoperative Complications (1)
Fluorometholone (1) · Ophthalmic Solutions (1) · Triamcinolone (1) · salicylhydroxamic acid (1)
United States (7)
Jillian F Ziemanski, OD, PhD (1) · Joshua Davidson, OD, FAAO (1) · Rosa A. Tang (1) · Samuel Minaker, MD (1) · Stephen C Pflugfelder, M.D. (1)